Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

332 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY).
Powell MA, Cibula D, O'Malley DM, Boere I, Shahin MS, Savarese A, Chase DM, Gilbert L, Black D, Herrstedt J, Sharma S, Kommoss S, Gold MA, Thijs AM, Ring K, Bolling MF, Buscema J, Gill SE, Nowicki P, Nevadunsky N, Callahan M, Willmott L, McCourt C, Billingsley C, Ghamande SA, He Z, Balas MM, Stevens S, Fleming E, Mirza MR. Powell MA, et al. Gynecol Oncol. 2024 Nov 11;192:40-49. doi: 10.1016/j.ygyno.2024.10.022. Online ahead of print. Gynecol Oncol. 2024. PMID: 39531903
A Plain Language Summary of "Dostarlimab for primary advanced or recurrent endometrial cancer".
Mirza MR, Chase DM, Slomovitz BM, Christensen RD, Novák Z, Black D, Gilbert L, Sharma S, Valabrega G, Landrum LM, Hanker LC, Stuckey A, Boere I, Gold MA, Auranen A, Pothuri B, Cibula D, McCourt C, Raspagliesi F, Shahin MS, Gill SE, Monk BJ, Buscema J, Herzog TJ, Copeland LJ, Tian M, He Z, Stevens S, Zografos E, Coleman RL, Powell MA. Mirza MR, et al. Among authors: powell ma. Future Oncol. 2024 Jul 11:1-18. doi: 10.2217/fon-2023-0940. Online ahead of print. Future Oncol. 2024. PMID: 38990090
Safety of dostarlimab in combination with chemotherapy in patients with primary advanced or recurrent endometrial cancer in a phase III, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY).
Auranen A, Powell MA, Sukhin V, Landrum LM, Ronzino G, Buscema J, Bauerschlag D, Lalisang R, Bender D, Gilbert L, Armstrong A, Safra T, Nevadunsky N, Sebastianelli A, Slomovitz B, Ring K, Coleman R, Podzielinski I, Stuckey A, Teneriello M, Gill S, Pothuri B, Willmott L, Sharma S, Dabrowski C, Antony G, Stevens S, Mirza MR, Fleming E. Auranen A, et al. Among authors: powell ma. Ther Adv Med Oncol. 2024 Sep 28;16:17588359241277656. doi: 10.1177/17588359241277656. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 39346117 Free PMC article.
A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
Martin LP, Sill M, Shahin MS, Powell M, DiSilvestro P, Landrum LM, Gaillard SL, Goodheart MJ, Hoffman J, Schilder RJ. Martin LP, et al. Gynecol Oncol. 2014 Mar;132(3):526-30. doi: 10.1016/j.ygyno.2013.12.018. Epub 2013 Dec 18. Gynecol Oncol. 2014. PMID: 24361733 Free PMC article. Clinical Trial.
A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer.
Aghajanian C, Filiaci V, Dizon DS, Carlson JW, Powell MA, Secord AA, Tewari KS, Bender DP, O'Malley DM, Stuckey A, Gao J, Dao F, Soslow RA, Lankes HA, Moore K, Levine DA. Aghajanian C, et al. Among authors: powell ma. Gynecol Oncol. 2018 Aug;150(2):274-281. doi: 10.1016/j.ygyno.2018.05.018. Epub 2018 May 24. Gynecol Oncol. 2018. PMID: 29804638 Free PMC article. Clinical Trial.
332 results